Image
Collaborative Careā„¢

Looking Under the Surface in Pediatric Atopic Dermatitis

Collaborative Care for Better Patient Outcomes

 

This activity is jointly provided by Global Education Group and Integritas Communications.

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of pediatricians and other clinicians who treat pediatric and adolescent patients with moderate-to-severe atopic dermatitis.

Statement of Need/Program Overview

Atopic dermatitis is a common, chronic, inflammatory disease that manifests primarily in the skin, although research has uncovered potentially deleterious effects in other organ systems throughout the body.1,2 The disease-related physical and biopsychosocial burdens of this condition can have substantial effects on patient and parent/caregiver quality of life, particularly in pediatric and adolescent patients with moderate-to-severe disease.3,4 A better understanding of disease etiology has supported the development of new approaches to disease characterization and targeted therapies.5,6 As a result, the first biologic therapy is now available to treat adult patients with moderate-to-severe disease. Further, this biologic therapy and other advanced treatments are currently under investigation for pediatric and adolescent patients, with some positive outcomes recently reported.7-9 With novel therapies emerging for pediatric and adolescent patients with difficult-to-treat atopic dermatitis, attendees will benefit from updates on the latest clinical trial data, treatment guidelines, and practical recommendations on how to translate this information into daily clinical decision-making.10 In this Collaborative Care Symposium™, a panel of recognized pediatric dermatology experts will review the latest evidence with the goal of providing recommendations to enhance overall patient outcomes. The faculty panel will discuss the pathophysiologic underpinnings of atopic dermatitis, best practices in comprehensive patient evaluations, and the latest evidence relating to disease management and referral for young patients with moderate-to-severe disease. In the final segment of the program, attendees will gain valuable insights as faculty members convey their own clinical experiences during discussions of representative case studies.

References

  1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015:66(suppl 1):8-16.
  2. Brunner PM, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. JInvest Dermatol. 2017;137(1):18-25.
  3. Carroll CL, et al. The burden of atopic dermatitis: impact on the patient, family, and society.Pediatr Dermatol. 2005;22(3):192-199.
  4. Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30. 
  5. Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858-873.
  6. Gandhi NA, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov2016;15(1):35-50.
  7. Paller, AS, et al. Therapeutic pipeline for atopic dermatitis: end of the drought?  J Allergy Clin Immunol. 2017;140(3):633-643.
  8. Simpson EL, et al. Dupilumab efficacy and safety in adolescents with moderate-to-severe atopic dermatitis: results from a multicenter, randomized, placebo-controlled, double-blind, parallel-group, phase 3 study. Presented at the 27thEADV Congress. September 12-16, 2018, Paris, France. Poster #4640.
  9. Cotter DG, et al. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol. 2018;78(3 suppl 1):S53-S62.
  10. Ariëns LFM, et al. Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy. Ther Adv Chronic Dis. 2018;9(9):159-170.

Educational Objective

After completing this activity, the participant should be better able to:

  • Describe the pathophysiologic mechanisms and risk factors associated with atopic dermatitis, including the rationales for targeted therapies
  • Longitudinally assess children and adolescents with atopic dermatitis for uncontrolled symptoms, comorbid conditions, and other biopsychosocial consequences for patients and their families
  • Discuss the clinical profiles, trial data, and prescribing considerations for targeted therapies for pediatric and adolescent patients with moderate-to-severe atopic dermatitis
  • Individualize therapeutic regimens for moderate-to-severe atopic dermatitis across pediatric health care settings based on ongoing symptoms, burdens, comorbidities, and shared clinical decision-making

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation

Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Nora Eldasher prior to the live event at neldasher@integritasgrp.com

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Register Now


Full Name *
Credentials *
Phone
You may receive up to 4 messages per live event. Terms & Privacy Policy can be found below.
Message and data rates may apply. Reply STOP to end or HELP for help.
Primary Specialty

By clicking Register, you accept our Privacy Policy.